Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.

Hong SH, Lee H, Lee SY, Sung YA, Hong YS, Song DK, Jung H, Kim MH

Open source

DOI
10.1136/bmjopen-2025-107482
Published
2026 Mar 19
Container
BMJ open
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-107482,
  title = {Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.},
  author = {Hong SH and Lee H and Lee SY and Sung YA and Hong YS and Song DK and Jung H and Kim MH},
  year = {2026},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2025-107482},
  url = {https://doi.org/10.1136/bmjopen-2025-107482}
}

RIS

TY  - JOUR
TI  - Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.
AU  - Hong SH
AU  - Lee H
AU  - Lee SY
AU  - Sung YA
AU  - Hong YS
AU  - Song DK
AU  - Jung H
AU  - Kim MH
PY  - 2026
JO  - BMJ open
DO  - 10.1136/bmjopen-2025-107482
UR  - https://doi.org/10.1136/bmjopen-2025-107482
ER  - 

APA

SH, H., H, L., SY, L., YA, S., YS, H., DK, S., H, J., & MH, K. (2026). Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study.. BMJ open. https://doi.org/10.1136/bmjopen-2025-107482

Source records